March 3, 2017 06:18 AM EST
Pharma

Sanofi steps up with a $645M deal to part­ner with As­traZeneca on a late-stage RSV an­ti­body

Arsalan Arif

Founder

Point­ing di­rect­ly at a piv­otal Phase III pro­gram, As­traZeneca has de­cid­ed to part­ner with Sanofi on an ex­per­i­men­tal an­ti­body for RSV.

The French phar­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

A service from the Financial Times